Showing 2 posts of 2 posts found.


Hutchmed announces phase 3 trial met primary endpoint for primary immune thrombocytopenia treatment

August 21, 2023
Research and Development HUTCHMED, Haematology, clinical trial, sovleplenib, thrombocytopenia

Hutchmed has announced that its phase 3 trial ESLIM-01 trial assessing the use of sovleplenib has met its primary endpoint …

Takeda and HUTCHMED’s cancer drug shown to prolong overall survival

June 16, 2023
Research and Development HUTCHMED, Oncology, Takeda, colorectal cancer

Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which is being developed by Japanese …

Latest content